Financials data is unavailable for this security.
View more
Year on year Tauns Laboratories Inc grew revenues 17.62% from 15.67bn to 18.43bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 90.26% net income growth from 3.03bn to 5.77bn.
| Gross margin | 67.80% |
|---|---|
| Net profit margin | 31.32% |
| Operating margin | 43.53% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in JPYView more
In 2024, Tauns Laboratories Inc increased its cash reserves by 657.40%, or 8.18bn. The company earned 9.94bn from its operations for a Cash Flow Margin of 53.89%. In addition the company generated 2.36bn cash from financing while 4.11bn was spent on investing.
| Cash flow per share | 64.50 |
|---|---|
| Price/Cash flow per share | 8.99 |
| Book value per share | 136.67 |
|---|---|
| Tangible book value per share | 99.46 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.61 |
|---|---|
| Quick ratio | 1.16 |
| Total debt/total equity | 0.698 |
|---|---|
| Total debt/total capital | 0.4111 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items increased 77.90%.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 37.67% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
More ▼
